Dr. Hafrun Fridriksdottir

Hafrun Fridriksdottir (Ph.D) became Executive Vice President, Global Research & Development (R&D) and part of Teva’s Executive Management team in November 2017. 

The Global R&D team is comprised of approximately 3,500 employees at 25 R&D sites across the globe responsible for the discovery, development, registration, medical affairs and patient safety activities for Teva’s generics, specialty and biosimilar pipeline and portfolio.

Teva Global R&D is uniquely positioned to drive access to quality medicines and support the company’s mission to improve the lives of patients with one of the biggest and most diverse generics portfolios in the industry, a growing specialty pipeline anchored in novel biologics, and one of the broadest biosimilar pipelines in healthcare today. 

Combining Teva’s resilient culture, scientific rigor, and extensive knowledge across a wide range of technologies, Teva Global R&D develops a broad range of small molecule medicines in a variety of delivery systems and dosage forms. As part of its growth strategy, Teva has made significant investments in next-generation biotechnology to combine its heritage in value creation and knowledge of complex molecules with “concept-to-clinic” capabilities to develop innovative biologics and biosimilars to feed its pipeline.

Prior to her current role, Hafrun served in a variety of R&D top management roles, both at Teva and in the industry, including as President of Global Generics R&D at Teva and Allegan plc, Senior Vice President of Global R&D at Actavis, and Divisional Manager of Development at Omega Pharma until its merger with Actavis.

Hafrun received an M.S. degree in pharmacy and a Ph.D. in physical pharmacy from the University of Iceland.